David J. Mauro - 05 Oct 2021 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Reporting relationship: Chief Medical Officer
Issuer ticker: PRLD
Reported as of: 05 Oct 2021
Net transaction value: -$436,000
SEC form: 4
Accepted by SEC: 06 Oct 2021, 18:02:41 UTC
Prior SEC filing: 09 Sep 2021
Next SEC filing: 04 May 2022
Source filing: View source filing
Reporting owner signature: /s/ Brian Piper, Attorney-in-Fact

Key filing fact

David J. Mauro filed Form 4 for Prelude Therapeutics Inc (PRLD) on 06 Oct 2021.

Key facts

This page summarizes David J. Mauro's Form 4 filing for Prelude Therapeutics Inc (PRLD).
5 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Oct 2021, 18:02.

Change

Previous filing in this sequence was filed on 09 Sep 2021.
Current net transaction value: -$436,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PRLD transaction

Common Stock

Options Exercise

Transaction value: $28,350
Shares: +15,000
Change %
Price: $1.89
Shares after: 15,000
Date: 05 Oct 2021
Ownership: Direct

PRLD transaction

Common Stock

Sale

Transaction value: $178,762
Shares: -5,908
Change %: -39%
Price: $30.26^*
Shares after: 9,092
Date: 05 Oct 2021
Ownership: Direct
Footnotes: F1, F2

PRLD transaction

Common Stock

Sale

Transaction value: $244,257
Shares: -7,803
Change %: -86%
Price: $31.30^*
Shares after: 1,289
Date: 05 Oct 2021
Ownership: Direct
Footnotes: F1, F3

PRLD transaction

Common Stock

Sale

Transaction value: $41,330
Shares: -1,289
Change %: -100%
Price: $32.06^*
Shares after: 0
Date: 05 Oct 2021
Ownership: Direct
Footnotes: F1, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PRLD transaction Derivative

Employee Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -15,000
Change %: -9.8%
Price: $0.000000
Shares after: 137,610
Date: 05 Oct 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $1.89
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.86 to $30.83, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.87 to $31.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

Footnote F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.87 to $32.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

Footnote F5

The stock option vested as to 25% of the total shares monthly on May 1, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.